Strategic takeaways from a decade of validation-related CRLs Strategic takeaways from a decade of validation-related CRLs Context Complete Response Letters (CRLs) issued by regulatory agencies such as the FDA, European Medicines Agency (EMA), and Medicines and Healthcare products Regulatory Agency (MHRA) represent a significant challenge for pharmaceutical and biotechnology companies. Specifically, validation-related CRLs highlight deficiencies in data supporting the marketing authorization of a product, often leading to increased time and costs associated with resubmissions. Understanding the underlying regulations, guidelines, and common deficiencies related to validation can inform and improve regulatory submissions, enabling companies to navigate the complex landscape of regulatory…